AstraZeneca's PD-L1 Works, But Probably Not Enough For Lung Cancer Filing
This article was originally published in Scrip
AstraZeneca PLC's chief medical officer has warned once again that a trial of the company's PD-L1 inhibitor durvalumab will not provide strong enough data to support a regulatory submission for the drug as a standalone treatment for advanced lung cancer. However, preliminary findings from the company's lead monotherapy trial, ATLANTIC, show that it does work.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.